Surrozen, Inc. reported that TCGFB, Inc. terminated their Collaboration Agreement on October 14, 2025, effective November 13, 2025, with no penalties for either party. The agreement involved up to $6 million in payments for antibody discovery services but will cease without any financial consequences.